- Home
- SGN vs WINT Comparison
SGN vs WINT Comparison
Compare SGN & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- WINT
- Stock Information
- Founded
- SGN 2019
- WINT 1992
- Country
- SGN United States
- WINT United States
- Employees
- SGN N/A
- WINT N/A
- Industry
- SGN
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGN
- WINT Health Care
- Exchange
- SGN Nasdaq
- WINT Nasdaq
- Market Cap
- SGN 1.1M
- WINT 996.6K
- IPO Year
- SGN 2023
- WINT 1995
- Fundamental
- Price
- SGN $0.62
- WINT $0.85
- Analyst Decision
- SGN
- WINT Hold
- Analyst Count
- SGN 0
- WINT 1
- Target Price
- SGN N/A
- WINT $350.00
- AVG Volume (30 Days)
- SGN 1.7M
- WINT 266.7K
- Earning Date
- SGN 05-19-2025
- WINT 05-20-2025
- Dividend Yield
- SGN N/A
- WINT N/A
- EPS Growth
- SGN N/A
- WINT N/A
- EPS
- SGN N/A
- WINT N/A
- Revenue
- SGN $615,551.00
- WINT N/A
- Revenue This Year
- SGN N/A
- WINT N/A
- Revenue Next Year
- SGN N/A
- WINT N/A
- P/E Ratio
- SGN N/A
- WINT N/A
- Revenue Growth
- SGN 100.13
- WINT N/A
- 52 Week Low
- SGN $0.44
- WINT $1.01
- 52 Week High
- SGN $36.72
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- SGN 45.99
- WINT 27.87
- Support Level
- SGN $0.44
- WINT $0.83
- Resistance Level
- SGN $0.60
- WINT $1.08
- Average True Range (ATR)
- SGN 0.07
- WINT 0.11
- MACD
- SGN 0.03
- WINT 0.04
- Stochastic Oscillator
- SGN 84.05
- WINT 5.76
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.